# BOND-003 (NCT04452591)

> Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04452591
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: CG Oncology, Inc.
- Conditions: Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer
- Interventions: Cretostimogene Grenadenorepvec; n-dodecyl-B-D-maltoside
- Enrollment: 190
- Primary outcome: Cohort C:
- Primary outcome: Cohort P:

## Commentary we found

- X threads: 36
- Podcasts: 12
- YouTube: 9

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=bond-003-nct04452591

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04452591", "email": "<work email>"}; the inbox owner confirms by the emailed link.